- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
TL1A antibody recognizes Tumor necrosis factor ligand superfamily member 15, also known as VEGI and encoded by the TNFSF15 gene. TL1A is a type II transmembrane cytokine that can be cleaved to generate a soluble form and is primarily expressed by endothelial cells, antigen-presenting cells, and activated immune cell populations. TL1A Antibody Recombinant Mouse MAb is developed to detect endogenous VEGI in research applications focused on inflammatory signaling and angiogenic regulation.
TL1A functions as a ligand for death receptor 3, also known as TNFRSF25, triggering downstream signaling pathways that regulate T cell activation, cytokine production, and apoptosis-related mechanisms. Through this receptor interaction, TNFSF15 plays a central role in modulating adaptive immune responses, particularly in T helper cell differentiation and effector function. In addition to its immune-regulatory activity, VEGI exerts anti-angiogenic effects by inhibiting endothelial cell proliferation and influencing vascular remodeling.
The TNFSF15 gene is located on chromosome 9q32 and produces a protein that participates in both membrane-bound and soluble signaling contexts. TL1A expression has been documented in vascular endothelium and inflamed tissues, and dysregulated TNFSF15 signaling has been associated with inflammatory bowel disease, autoimmune disorders, and tumor-associated vascular changes. In oncology research, VEGI has been investigated for its capacity to suppress tumor angiogenesis by limiting vascular support within the tumor microenvironment.
Because TL1A bridges vascular biology and immune activation, it remains an important target for studies examining endothelial-immune crosstalk and cytokine-driven inflammation. Altered expression of TNFSF15 may influence chronic inflammatory states and immune-mediated tissue injury.
Clone rVEGI/1283 is a recombinant mouse monoclonal antibody that recognizes TL1A and supports studies of TNFSF15-mediated signaling, immune regulation, and VEGI-associated angiogenic pathways.
Titration of the rTL1A antibody may be required for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
A full length human recombinant protein was used as the immunogen for this TL1A antibody.
Store the TL1A antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.